A Twelve-Year Experience with Adrenal Cortical Carcinoma in a Single Institution: Long-Term Survival after Surgical Treatment and Transcatheter Arterial Embolization

Soga, Hideo; Takenaka, Atsushi; Ooba, Takeshi; Nakano, Yuzo; Takeda, Masatoshi; Tanaka, Kazushi; Hara, Isao; Fujisawa, Masato

doi:10.1159/000200804

Cited by 23 publications

(18 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experience with percutaneous ablation has been described as a feasible approach, with outcomes at least comparable to those of local surgical resection 11,13 . Positive short‐term results are reported with both TAE and radioembolization 29,30 . When considering IGLTs, it is important to bear in mind that transarterial therapy is more often palliative in nature, while ablation is potentially extirpative and may be curative.…”

Section: Discussionmentioning

confidence: 99%

“…11,13 Positive short-term results are reported with both TAE and radioembolization. 29,30 When considering IGLTs, it is important to bear in mind that transarterial therapy is more often palliative in nature, while ablation is potentially extirpative and may be curative. Therefore, in situations in which the option of ablation or TACE exists, ablation may be more optimal, if a tumor-free margin by imaging can be achieved.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization

et al. 2021

View full text Add to dashboard Cite

show abstract

“…TACE, localized chemoembolization, is based on a selective embolization with injection of a high intratumor levels of cytotoxic substances with a minimum of systemic effects. Predictors of response were a size of <3 cm and high lipidol uptake (Soga et al, 2009 ).…”

Section: Metastatic Accmentioning

confidence: 99%

Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment

Libé

2015

Front. Cell Dev. Biol.

184

188

View full text Add to dashboard Cite

Adrenocortical carticnoma (ACC) is a rare malignancy with an incidence of 0.7–2.0 cases/million habitants/year. The diagnosis of malignancy relies on careful investigations of clinical, biological, and imaging features before surgery and pathological examination after tumor removal. Most patients present with steroid hormone excess or abdominal mass effects, but 15% of patients with ACC is initially diagnosed incidentally. After the diagnosis, in order to assess the ACC prognosis and establish an adequate basis for treatment decisions different tools are proposed. The stage classification proposed by the European Network for the Study of Adrenal Tumors (ENSAT) is recommended. Pathology reports define the Weiss score, the resection status and the proliferative index, including the mitotic count and the Ki67 index. As far as the treatment is concerned, in case of tumor limited to the adrenal gland, the complete resection of the tumor is the first option. Most patients benefit from adjuvant mitotane treatment. In metastatic disease, mitotane is the cornerstone of initial treatment, and cytotoxic drugs should be added in case of progression. Recently, the First International Randomized (FIRM-ACT) Trial in metastatic ACC reported the association between mitotane and etoposide/doxorubicin/cisplatin (EDP) as the new standard in first line treatment of ACC. In last years, new targeted therapies, including the IGF-1 receptor inhibitors, have been investigated, but their efficacy remains limited. Thus, new treatment concepts are urgently needed. The ongoing “omic approaches” and next-generation sequencing will improve our understanding of the pathogenesis and hopefully will lead to better therapies.

show abstract

“…Adrenal tumors are detected unexpectedly in 1% to 4% of all abdominal imaging studies, and approximately 5% of those incidentalomas are found as ACCs. 26 From Korean data, 4.3% of the 348 cases of adrenal incidentalomas were identified as ACC. 27 However, because of its rapid progression and poor prognosis, incidentally detected tumors are not restricted to a limited stage and are not associated with favorable survival.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features Associated With the Prognosis of Patients With Adrenal Cortical Carcinoma

Choi

Kwon²,

Jeon³

et al. 2016

Medicine

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare tumor with a poor prognosis. Identification of clinicopathological features and molecular prognostic markers is important for the treatment of ACC. The aim of this study was to evaluate the clinical and histopathological features of ACC for prognostic prediction.This retrospective cohort study included 86 patients pathologically confirmed with ACC in a single center. Ki-67 index was evaluated by immunohistochemical staining of paraffin-embedded samples.The median age of the 86 (46 male and 40 female) patients with ACC was 49 years old (range 21–78), and the mean primary tumor size was 12.2 ± 5.2 cm. ACCs were incidentally found in 29 patients (34%). Three patients (3%) had bilateral ACC, and 59 patients (69%) had distant metastasis (37 synchronous and 22 metachronous). Twenty-four patients (28%) had symptoms from hormone excess or mass effects, and 25 patients (29%) had nonspecific symptoms. The 5-year survival rate for ACC was 28%. Sixty patients underwent surgical treatment, including 37 patients with an R0 resection. Tumor size, Ki-67 index, stage, and resection status were independently associated with overall survival by multivariate analysis. In patients with R0 resection, recurrence was significantly associated with larger tumor size and functional tumor.Tumor size, Ki-67 index, stage, and resection status are important prognostic indicators of survival in ACC patients.

show abstract

A Twelve-Year Experience with Adrenal Cortical Carcinoma in a Single Institution: Long-Term Survival after Surgical Treatment and Transcatheter Arterial Embolization

Cited by 23 publications

References 61 publications

Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization

Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization

Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment

Clinicopathological Features Associated With the Prognosis of Patients With Adrenal Cortical Carcinoma

Contact Info

Product

Resources

About